Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD0466 |
Synonyms | |
Therapy Description |
AZD0466 is a nanoparticle comprised of the BH3 mimetic AZD4320 linked to a pegylated poly-lysine dendrimer, which is cleaved to release AZD4320, leading to inhibition of BCL-XL and BCL2, and potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 34050131). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0466 | AZD-0466|AZD 0466 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | AZD0466 is a nanoparticle comprised of the BH3 mimetic AZD4320 linked to a pegylated poly-lysine dendrimer, which is cleaved to release AZD4320, leading to inhibition of BCL-XL and BCL2, and potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 34050131). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04214093 | Phase I | AZD0466 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Terminated | USA | 0 |
NCT04865419 | Phase Ib/II | AZD0466 + Voriconazole AZD0466 | Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies | Terminated | USA | ITA | FRA | DEU | AUS | 1 |
NCT05205161 | Phase Ib/II | AZD0466 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | AUS | 2 |